 |
|
Featured Clinical Trials Supported by the National Cancer Institute
Today, hundreds of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials featured in the NCI Cancer Bulletin and demonstrates the breadth of clinical cancer research supported by the NCI.
To find other cancer trials open to enrollment:
- Call the National Cancer Institute’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the basic PDQ search form to look online for trials listed in NCI's clinical trials database. The top of the form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call the National Cancer Institute’s Clinical Studies Support Center at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
1. Adjuvant Aromatase Inhibitor Therapy for Breast Cancer
(Posted: 05/13/2008, Updated: 08/11/2008) - In this clinical trial, postmenopausal women with hormone receptor-positive breast cancer that has been surgically removed will be randomly assigned to receive either anastrozole or exemestane for five years.
2. Refining Treatment for Gastrointestinal Stromal Tumors
(Posted: 08/05/2008) - In this randomized trial, patients with unresectable or metastatic GIST will receive imatinib therapy with or without the addition of bevacizumab. Researchers hope that the combination of imatinib and bevacizumab will help extend progression-free survival.
3. Treating Relapsed or Refractory B-cell Lymphomas
(Posted: 07/22/2008) - Scientists are studying the drug flavopiridol in this early phase clinical trial to see if it can be effective in treating diffuse large B-cell lymphoma and mantle cell lymphoma that has relapsed or been resistant to treatment.
4. New Drugs for Multiple Myeloma Consolidation Therapy
(Posted: 07/08/2008) - In this trial, newly diagnosed multiple myeloma patients who have undergone induction therapy will be treated with consolidation therapy consisting of dexamethasone and the drug bortezomib, and some will also be randomly assigned to receive a third drug called lenalidomide.
5. Treatment for Advanced Carcinoid Tumors
(Posted: 06/24/2008) - In this trial, patients with advanced nueroendocrine carcinoid tumors that have spread (metastasized) or that cannot be surgically removed (unresectable) will be randomly assigned to receive the drug octreotide acetate along with either bevacizumab or another drug called interferon alfa.
1 2 3 4 Next >
|
|
|
